Oncological Genetics in Istanbul
Oncological genetics combines genomic profiling, hereditary cancer risk assessment, and precision medicine to personalize cancer treatment and prevention in Istanbul JCI-accredited centers.
Services
- NGS (Next-Generation Sequencing): Comprehensive genomic profiling (300-500 gene panels). Identifies actionable mutations: BRCA1/2, EGFR, ALK, KRAS, BRAF, HER2, NTRK, RET, MET, ROS1
- ctDNA / Liquid Biopsy: Cell-free DNA in blood. Treatment monitoring, minimal residual disease detection, early recurrence detection
- Hereditary Cancer Risk: BRCA1/2 testing for breast/ovarian. Lynch syndrome (MLH1, MSH2, MSH6, PMS2) for colorectal/endometrial. PALB2, ATM, CHEK2
- Tumor Mutational Burden (TMB): High TMB → pembrolizumab response. MSI-H/dMMR → immunotherapy eligibility
- HRD (Homologous Recombination Deficiency): BRCA-like tumors → PARP inhibitor eligibility (olaparib, niraparib, rucaparib)
PRECISION MEDICINE IMPACT
Comprehensive genomic profiling finds actionable mutation in 55-65% of solid tumors, enabling targeted therapy matching and clinical trial eligibility assessment.
Cost
NGS panel (300+ genes): $1,500-3,000 Istanbul vs $3,000-8,000 USA. BRCA1/2 germline testing: $300-600 vs $1,500-3,000 USA.